

2015 PHARMACEUTICALS RESEARCH REVIEW



PHM099E
January 2016

Various Analysts
Project Analyst

ISBN: 1-62296-196-X



BCC Research
49 Walnut Park, Building 2
Wellesley, MA 02481 USA
866-285-7215 (toll-free within the USA),
or (+1) 781-489-7301
www.bccresearch.com
information@bccresearch.com

TABLE OF CONTENTS

TOPIC	PAGE NO.
CHAPTER 1 FOREWORD	2
CHAPTER 2 CANCER VACCINES: TECHNOLOGIES AND GLOBAL MARKETS (REPORT PHM173A)	4
INTRODUCTION	4
STUDY OBJECTIVES	4
REASONS FOR DOING THIS STUDY	4
CONTRIBUTIONS OF THE STUDY AND FOR WHOM	4
SCOPE OF THE STUDY	5
METHODOLOGY	5
INFORMATION SOURCES	5
ANALYSTS' CREDENTIALS	5
RELATED BCC RESEARCH REPORTS	6
EXECUTIVE SUMMARY	6
<i>TABLE 1 GLOBAL MARKET FOR CANCER VACCINES BY REGION, THROUGH 2019 (\$ MILLIONS)</i>	8
<i>FIGURE 1 GLOBAL MARKET FOR CANCER VACCINES BY REGION, 2012-2019 (\$ MILLIONS)</i>	8
DEFINITIONS	8
HISTORY OF CANCER AND ITS MANAGEMENT	9
<i>TABLE 2 HISTORY OF CANCER AND ITS MANAGEMENT</i>	10
CLASSIFICATION OF CANCERS	11
CLASSIFICATION BY SITE OF ORIGIN	11
CLASSIFICATION BY TISSUE TYPE	12
Carcinoma	12
Adenocarcinoma	12
Squamous Cell Carcinoma	12
Sarcomas	12
Myeloma	13
Leukemias	13
Lymphomas	13
Mixed Types	13
CLASSIFICATION BY GRADE	13
SYMPTOMS OF CANCER	14
LOCAL SYMPTOMS	14
SYSTEMIC SYMPTOMS	14
SYMPTOMS OF THE SPREAD OF CANCER OR METASTASIS	14
RISK FACTORS	14
CANCER-CAUSING AGENTS	14
CHEMICAL CARCINOGENS	15
IONIZING RADIATION	15
VIRAL AND BACTERIAL INFECTIONS	15
GENETIC OR INHERITED CANCERS	15
HORMONAL CHANGES	15
IMMUNE SYSTEM DYSFUNCTION	16
COMMERCIALLY AVAILABLE CANCER VACCINES	16

TOPIC	PAGE NO.
LIVER CANCER	16
PROSTATE CANCER	18
Radical Retropubic Prostatectomy	18
Laparoscopic Prostatectomy	18
Radical Perineal Prostatectomy	18
Transurethral Resection of the Prostate	19
CERVICAL CANCER	19
PREVALENCE	20
<i>TABLE 3 ESTIMATED GLOBAL INCIDENCE, MORTALITY AND FIVE-YEAR PREVALENCE OF CANCER, 2012 (THOUSANDS)</i>	21
INCIDENCE AND MORTALITY RATE	21
<i>TABLE 4 GLOBAL INCIDENCE AND MORTALITY RATES OF CANCER, 2012</i>	21
CANCER STATISTICS BY GEOGRAPHY	22
<i>TABLE 5 ESTIMATED U.S. INCIDENCE, MORTALITY AND FIVE-YEAR PREVALENCE, 2012</i>	22
<i>TABLE 6 ESTIMATED EUROPEAN UNION INCIDENCE, MORTALITY AND FIVE-YEAR PREVALENCE, 2012</i>	22
GLOBAL CANCER STATISTICS BY TYPE OF CANCER	22
<i>TABLE 7 ESTIMATED GLOBAL CANCER STATISTICS BY TYPE OF CANCER IN BOTH SEXES, 2012 (IN NUMBERS)</i>	23
<i>TABLE 8 ESTIMATED GLOBAL CANCER STATISTICS BY TYPE OF CANCER IN MEN, 2012 (IN NUMBERS)</i>	23
<i>TABLE 9 ESTIMATED GLOBAL CANCER STATISTICS BY TYPE OF CANCER IN WOMEN, 2012 (IN NUMBERS)</i>	24
VARIOUS FORMS OF CANCER STATISTICS BY GEOGRAPHY	24
<i>TABLE 10 ESTIMATED CANCER INCIDENCE, MORTALITY AND FIVE-YEAR PREVALENCE IN THE U.S., 2012</i>	25
<i>TABLE 11 ESTIMATED CANCER INCIDENCE, MORTALITY AND FIVE-YEAR PREVALENCE IN EUROPE, 2012</i>	25
<i>TABLE 12 ESTIMATED CANCER INCIDENCE, MORTALITY AND FIVE-YEAR PREVALENCE IN ASIA, 2012</i>	26
CANCER AND THE IMMUNE SYSTEM	26
MOLECULAR BIOLOGY OF CANCER	27
CANCER PATHOPHYSIOLOGY	27
ONCOGENES	27
TUMOR SUPPRESSOR GENES	28
PREVENTION OF CANCER	28
MANAGEMENT OF CANCER	28
SURGERY	29
CHEMOTHERAPY	29
RADIATION THERAPY	29
TARGETED THERAPY	29
IMMUNOTHERAPY	29
HORMONAL THERAPY	29
BIOLOGICAL THERAPY	30
CANCER VACCINES	30
CLASSIFICATION OF CANCER VACCINES	30
Preventive (or Prophylactic) Vaccines	30
Therapeutic Vaccines	30

TOPIC	PAGE NO.
MANUFACTURING/CREATING VACCINES	31
TYPES OF CANCER VACCINES	31
Tumor Cell Vaccines	31
Cancer Stem Cell Vaccines	32
Peptide/Protein Vaccines	32
Antigen Vaccines	33
Anti-idiotypic Vaccines	33
Heat Shock Protein Vaccines	33
DNA and Vector-Based Vaccines	33
CHAPTER 3 THERAPEUTICS FOR "SILENT" CANCERS (REPORT PHM169A)	36
INTRODUCTION	36
STUDY GOALS AND OBJECTIVES	36
REASONS FOR DOING THE STUDY	36
SCOPE OF REPORT	36
MARKET ANALYSES AND FORECASTS	36
METHODOLOGY	37
INTENDED AUDIENCE	37
INFORMATION SOURCES	37
ANALYST'S CREDENTIALS	37
RELATED BCC RESEARCH REPORTS	37
SUMMARY	38
<i>TABLE 13 GLOBAL MARKET FOR "SILENT" CANCERS, THROUGH 2019 (\$ MILLIONS)</i>	39
<i>FIGURE 2 GLOBAL MARKET SHARE FOR "SILENT" CANCERS, 2013 AND 2019 (%)</i>	39
OVERVIEW	40
CANCER: A GLOBAL PERSPECTIVE	40
GROWING PROBLEM	41
MARKET DYNAMICS	42
SOME LEADING ANTICANCER DRUGS	42
DRUG CATEGORIES	42
ASYMPTOMATIC CANCER	44
TELLTALE GENES	45
TUMOR MARKERS	46
CHAPTER 4 INCRETIN-BASED DRUGS: MARKETS FOR DIABETES THERAPIES AND DEVELOPING TREATMENTS (REPORT PHM162A)	48
INTRODUCTION	48
STUDY GOALS AND OBJECTIVES	48
REASONS FOR DOING THIS STUDY	48
SCOPE OF REPORT	48
INTENDED AUDIENCE	49
METHODOLOGY	49
INFORMATION SOURCES	49
ANALYST'S CREDENTIALS	49
RELATED BCC RESEARCH REPORTS	49
EXECUTIVE SUMMARY	50
INCRETINS FILL NEED FOR GLYCEMIC CONTROL	51
TRENDS IN DISPENSING AND SALES	52

TOPIC	PAGE NO.
<i>TABLE 14 GLOBAL MARKET FOR INCRETIN-BASED THERAPEUTICS, THROUGH 2019 (\$ MILLIONS)</i>	53
<i>FIGURE 3 GLOBAL MARKET FOR INCRETIN-BASED THERAPEUTICS, 2012-2019 (\$ MILLIONS)</i>	54
GEOGRAPHICAL SHIFTS	55
KEY DRIVERS	55
KEY CHALLENGES	55
KEY TRENDS	56
OVERVIEW AND MARKET FORECAST	56
<i>FIGURE 4 THE INCRETIN EFFECT ILLUSTRATED</i>	57
<i>FIGURE 5 PERCENTAGE OF DISPENSED PRESCRIPTIONS FOR NON-INSULIN ANTIDIABETICS, 2012 (%)</i>	58
DATA ON WHERE INCRETINS FIT	59
<i>FIGURE 6 PERCENTAGE OF DISPENSED PRESCRIPTIONS FOR GLP-1 RECEPTOR AGONISTS, 2012 (%)</i>	60
<i>FIGURE 7 PERCENTAGE OF DISPENSED PRESCRIPTIONS FOR DPP-4 INHIBITORS, 2012 (%)</i>	60
FOR SOME, A GLP-1 FOCUS	61
<i>TABLE 15 DIFFERENCES BETWEEN THE INCRETIN THERAPIES</i>	62
STANDARD DIABETIC TREATMENTS	63
METFORMIN	63
SULFONYLUREAS (SU)	64
THIAZOLIDINEDIONE (TZD)	64
ALPHA-GLUCOSIDASE INHIBITORS	65
INSULIN TREATMENT	66
Long-Acting Insulin	67
Intermediate-Acting Insulin	67
Regular or Short-acting Insulin	67
Rapid-Acting Insulin	67
<i>TABLE 16 ADVANTAGES TO ADDING INCRETIN THERAPY</i>	67
OTHER NEW TREATMENTS	68
DIABETES FURTHER EXPLAINED	70
TYPES OF DIABETES	71
Type 1	71
Type 2	71
Gestational Diabetes	72
Impaired Glucose Tolerance (IGT) and Impaired Fasting Glycemia (IFG)	72
CARE MODEL UPDATED WITH INCRETINS	72
CONDITIONS RELATED TO DIABETES	74
Obesity	74
<i>FIGURE 8 ADA'S STANDARD OF MEDICAL CARE IN DIABETES, 2014</i>	74
Cardiovascular Disease	75
Pancreatitis	76
Cancer	77
<i>TABLE 17 CURRENT THINKING ON DIABETES MEDICATIONS AND CANCER RISK</i>	78
Polycystic Ovary Syndrome	78
COMPLICATIONS AND COMORBIDITIES	78
<i>TABLE 18 COMPLICATIONS/COMORBID CONDITIONS FROM DIABETES</i>	78

TOPIC	PAGE NO.
INCRETIN THERAPIES	79
<i>TABLE 19 COMMERCIALIZED INCRETIN THERAPY</i>	80
GLP-1 RECEPTOR AGONISTS	80
COMMERCIALIZED GLP-1 RECEPTOR AGONISTS	82
Exenatide	82
Liraglutide	83
Dulaglutide	84
Albiglutide	85
Lixisenatide	86
COMMERCIALIZED DPP-4 INHIBITORS	86
Linagliptin	87
Sitagliptin	88
Vildagliptin	88
Saxagliptin	88
Alogliptin	89
Teneligliptin	91
Anagliptin	92
Gemigliptin	92
MARKET LANDSCAPE	93
<i>TABLE 20 NUMBER OF COMMERCIALIZED INCRETIN-BASED THERAPEUTICS, 2014 AND 2019 (UNITS)</i>	93
<i>FIGURE 9 NUMBER OF COMMERCIALIZED INCRETIN-BASED THERAPEUTICS, 2014 AND 2019 (UNITS)</i>	93
<i>FIGURE 10 MARKET SHARE OF INCRETIN-BASED THERAPEUTICS, BY THERAPEUTIC AREA, 2014 AND 2019 (% OF REVENUE BY THERAPEUTIC AREA)</i>	94
<i>FIGURE 11 MARKET SHARE OF COMMERCIALIZED INCRETIN-BASED THERAPEUTICS, BY INCRETIN TYPE, 2014 AND 2019 (% OF REVENUE BY INCRETIN TYPE)</i>	96
<i>FIGURE 12 MARKET SHARE OF COMMERCIALIZED GLP-1 RECEPTOR AGONISTS, BY DOSING FREQUENCY, 2014 AND 2019 (%)</i>	96
DEALS IN THE INCRETIN MARKET	97
<i>TABLE 21 MAJOR AGREEMENTS FOR INCRETIN-BASED THERAPY DEVELOPMENT</i>	98
CHAPTER 5 GLOBAL MARKETS FOR ORPHAN DRUGS (REPORT PHM038E)	103
INTRODUCTION	103
STUDY OBJECTIVES	103
REASONS FOR DOING THIS REPORT	103
CONTRIBUTIONS OF THE REPORT AND FOR WHOM	104
SCOPE OF THE REPORT	104
METHODOLOGY	104
INFORMATION SOURCES	104
ANALYSTS' CREDENTIALS	104
RELATED BCC RESEARCH REPORTS	105
EXECUTIVE SUMMARY	105
<i>TABLE 22 GLOBAL REVENUES OF ORPHAN DRUGS BY TYPE, THROUGH 2019 (\$ MILLIONS)</i>	107
<i>FIGURE 13 GLOBAL REVENUES OF ORPHAN DRUGS BY TYPE, 2012-2019 (\$ MILLIONS)</i>	107
OVERVIEW	107
DIFFERENT KINDS OF ORPHAN DRUGS	107

TOPIC	PAGE NO.
BIOLOGICAL ORPHAN DRUGS	108
CHEMICAL OR NON-BIOLOGICAL ORPHAN DRUGS	108
GLOBAL DEFINITIONS OF RARE DISEASES	108
U.S.	108
EU	108
TAIWAN	109
JAPAN	109
AUSTRALIA	109
<i>TABLE 23 RARE DISEASES AND THEIR PREVALENCE</i>	109
PERSPECTIVE AND HISTORY OF ORPHAN DRUG ACT	110
<i>TABLE 24 HISTORY OF RARE DISEASES AND ORPHAN DRUG LEGISLATION</i>	110
LEGISLATION IN THE U.S.	112
NATIONAL ORGANIZATION FOR RARE DISORDERS (NORD)	112
ORPHAN DRUG ACT	112
<i>TABLE 25 AMENDMENTS OF U.S. ORPHAN DRUG ACT</i>	113
GLOBAL PERSPECTIVE OF ORPHAN DRUGS	113
EUROPE	113
AUSTRALIA	114
SINGAPORE	115
JAPAN	115
TAIWAN	116
CANADA	116
BRAZIL	116
SOUTH KOREA	117
ISRAEL	117
RUSSIA	117
KAZAKHSTAN	118
<i>TABLE 26 COMPARISON OF ORPHAN DRUG LEGISLATION IN THE U.S., EU, AUSTRALIA AND JAPAN</i>	118
IMPACT OF ORPHAN DRUG ACT	119
<i>TABLE 27 NUMBER OF FDA ORPHAN DRUG DESIGNATIONS AND APPROVALS PER YEAR, 1983-2014</i>	120
DIFFERENCE BETWEEN ORPHAN DRUGS VS NORMAL DRUGS	120
<i>TABLE 28 DIFFERENCES BETWEEN ORPHAN DRUGS AND NORMAL DRUGS</i>	120
APPLICATION OF APPROVED ORPHAN DRUGS	121
<i>TABLE 29 APPROVED ORPHAN DRUGS AND THEIR THERAPEUTIC USE</i>	121
CHAPTER 6 GLOBAL MARKETS FOR INFECTIOUS DISEASE TREATMENTS (REPORT PHM061C)	125
INTRODUCTION	125
STUDY GOALS AND OBJECTIVES	125
REASONS FOR DOING THE STUDY	125
SCOPE OF REPORT	126
INTENDED AUDIENCE	126
METHODOLOGIES AND INFORMATION SOURCES	126
ANALYST'S CREDENTIALS	126
RELATED BCC RESEARCH REPORTS	127
SUMMARY	127

TOPIC	PAGE NO.
<i>TABLE 30 GLOBAL MARKET FOR INFECTIOUS DISEASES DIAGNOSTIC, VACCINE AND PHARMACEUTICAL PRODUCTS, THROUGH 2021 (\$ MILLIONS)</i>	128
<i>FIGURE 14 GLOBAL MARKET SHARE FOR INFECTIOUS DISEASE DIAGNOSTIC, VACCINE AND PHARMACEUTICAL PRODUCTS, 2016 AND 2021 (%)</i>	128
OVERVIEW OF THE GLOBAL STATE OF INFECTIOUS DISEASE DIAGNOSIS, VACCINES AND TREATMENT	130
TOP GLOBAL CAUSES OF DEATH	130
<i>TABLE 31 GLOBAL PERCENTAGE OF DEATHS BY TYPE OF DISEASE, CAUSE, INCOME LEVEL, 2012* (%)</i>	131
MAJOR INFECTIOUS DISEASES	131
<i>TABLE 32 SELECTED WORLDWIDE MAJOR INFECTIOUS DISEASES, 2013* (NUMBER OF CASES, TREATMENT OPTIONS)</i>	132
HISTORICAL IMPACT OF INFECTIOUS DISEASES	132
LEADING CAUSES OF GLOBAL DEATHS	133
Transmission of Infectious Diseases	133
LINKING INFECTIOUS DISEASE TO CANCER	133
TREATMENTS FOR INFECTIOUS DISEASES	133
PREVENTION	133
VACCINATION	134
WHO Global Vaccination Action Plan	134
<i>FIGURE 15 GLOBAL IMMUNIZATION COVERAGE, 2014 (%)</i>	134
Challenges to Meet WHO Guidelines	135
GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET	135
TYPES OF DIAGNOSTIC TESTING	135
FLUORESCENT IMMUNOASSAY (FIA)	136
Direct Fluorescent Antibody Testing (FA)	136
Indirect Fluorescent Antibody Testing (IFA)	136
ENZYME IMMUNOASSAY (EIA)	137
Basic EIA	137
Enzyme-Linked Immunosorbent Assay (ELISA)	137
GENE PROBE ANALYSIS	138
Polymerase Chain Reaction Amplification (PCR)	138
Nucleic Acid Amplification Test (NAT)	138
Transcription-Mediated Amplification (TMA)	139
Nucleic Acid Sequence-Based Amplification (NASBA)	139
GLOBAL MARKET FOR INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS	139
<i>TABLE 33 GLOBAL MARKET FOR HUMAN INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS, THROUGH 2021 (\$ MILLIONS)</i>	140
GLOBAL INFECTIOUS DISEASE VACCINE MARKET	140
<i>TABLE 34 GLOBAL MARKET FOR HUMAN INFECTIOUS DISEASE VACCINE PRODUCTS, THROUGH 2021 (\$ MILLIONS)</i>	140
GLOBAL INFECTIOUS DISEASE PHARMACEUTICAL MARKET	140
<i>TABLE 35 GLOBAL MARKET FOR HUMAN INFECTIOUS DISEASE PHARMACEUTICAL PRODUCTS, THROUGH 2021 (\$ MILLIONS)</i>	141
VACCINE OPPORTUNITIES	141
CHILDHOOD DISEASES	141
GLOBAL HUMANITARIAN AGENCIES	141
PHARMACEUTICAL OPPORTUNITIES	142
THE EMERGENCE OF GENE THERAPY	142

TOPIC	PAGE NO.
MERGERS AND ACQUISITIONS	142
<i>TABLE 36 SELECTED MERGERS AND ACQUISITIONS, 2012 TO 2015 (\$ MILLIONS)</i>	143

LIST OF TABLES

TABLE HEADING	PAGE NO.
TABLE 1 GLOBAL MARKET FOR CANCER VACCINES BY REGION, THROUGH 2019 (\$ MILLIONS)	8
TABLE 2 HISTORY OF CANCER AND ITS MANAGEMENT	10
TABLE 3 ESTIMATED GLOBAL INCIDENCE, MORTALITY AND FIVE-YEAR PREVALENCE OF CANCER, 2012 (THOUSANDS)	21
TABLE 4 GLOBAL INCIDENCE AND MORTALITY RATES OF CANCER, 2012	21
TABLE 5 ESTIMATED U.S. INCIDENCE, MORTALITY AND FIVE-YEAR PREVALENCE, 2012	22
TABLE 6 ESTIMATED EUROPEAN UNION INCIDENCE, MORTALITY AND FIVE-YEAR PREVALENCE, 2012	22
TABLE 7 ESTIMATED GLOBAL CANCER STATISTICS BY TYPE OF CANCER IN BOTH SEXES, 2012 (IN NUMBERS)	23
TABLE 8 ESTIMATED GLOBAL CANCER STATISTICS BY TYPE OF CANCER IN MEN, 2012 (IN NUMBERS)	23
TABLE 9 ESTIMATED GLOBAL CANCER STATISTICS BY TYPE OF CANCER IN WOMEN, 2012 (IN NUMBERS)	24
TABLE 10 ESTIMATED CANCER INCIDENCE, MORTALITY AND FIVE-YEAR PREVALENCE IN THE U.S., 2012	25
TABLE 11 ESTIMATED CANCER INCIDENCE, MORTALITY AND FIVE-YEAR PREVALENCE IN EUROPE, 2012	25
TABLE 12 ESTIMATED CANCER INCIDENCE, MORTALITY AND FIVE-YEAR PREVALENCE IN ASIA, 2012	26
TABLE 13 GLOBAL MARKET FOR "SILENT" CANCERS, THROUGH 2019 (\$ MILLIONS)	39
TABLE 14 GLOBAL MARKET FOR INCRETIN-BASED THERAPEUTICS, THROUGH 2019 (\$ MILLIONS)	53
TABLE 15 DIFFERENCES BETWEEN THE INCRETIN THERAPIES	62
TABLE 16 ADVANTAGES TO ADDING INCRETIN THERAPY	67
TABLE 17 CURRENT THINKING ON DIABETES MEDICATIONS AND CANCER RISK	78
TABLE 18 COMPLICATIONS/COMORBID CONDITIONS FROM DIABETES	78
TABLE 19 COMMERCIALIZED INCRETIN THERAPY	80
TABLE 20 NUMBER OF COMMERCIALIZED INCRETIN-BASED THERAPEUTICS, 2014 AND 2019 (UNITS)	93
TABLE 21 MAJOR AGREEMENTS FOR INCRETIN-BASED THERAPY DEVELOPMENT	98
TABLE 22 GLOBAL REVENUES OF ORPHAN DRUGS BY TYPE, THROUGH 2019 (\$ MILLIONS)	107
TABLE 23 RARE DISEASES AND THEIR PREVALENCE	109
TABLE 24 HISTORY OF RARE DISEASES AND ORPHAN DRUG LEGISLATION	110
TABLE 25 AMENDMENTS OF U.S. ORPHAN DRUG ACT	113
TABLE 26 COMPARISON OF ORPHAN DRUG LEGISLATION IN THE U.S., EU, AUSTRALIA AND JAPAN	118
TABLE 27 NUMBER OF FDA ORPHAN DRUG DESIGNATIONS AND APPROVALS PER YEAR, 1983-2014	120
TABLE 28 DIFFERENCES BETWEEN ORPHAN DRUGS AND NORMAL DRUGS	120
TABLE 29 APPROVED ORPHAN DRUGS AND THEIR THERAPEUTIC USE	121
TABLE 30 GLOBAL MARKET FOR INFECTIOUS DISEASES DIAGNOSTIC, VACCINE AND PHARMACEUTICAL PRODUCTS, THROUGH 2021 (\$ MILLIONS)	128
TABLE 31 GLOBAL PERCENTAGE OF DEATHS BY TYPE OF DISEASE, CAUSE, INCOME LEVEL, 2012* (%)	131
TABLE 32 SELECTED WORLDWIDE MAJOR INFECTIOUS DISEASES, 2013* (NUMBER OF CASES, TREATMENT OPTIONS)	132

TABLE HEADING	PAGE NO.
TABLE 33 GLOBAL MARKET FOR HUMAN INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS, THROUGH 2021 (\$ MILLIONS)	140
TABLE 34 GLOBAL MARKET FOR HUMAN INFECTIOUS DISEASE VACCINE PRODUCTS, THROUGH 2021 (\$ MILLIONS)	140
TABLE 35 GLOBAL MARKET FOR HUMAN INFECTIOUS DISEASE PHARMACEUTICAL PRODUCTS, THROUGH 2021 (\$ MILLIONS)	141
TABLE 36 SELECTED MERGERS AND ACQUISITIONS, 2012 TO 2015 (\$ MILLIONS)	143

LIST OF FIGURES

FIGURE TITLE	PAGE NO.
FIGURE 1 GLOBAL MARKET FOR CANCER VACCINES BY REGION, 2012-2019 (\$ MILLIONS)	8
FIGURE 2 GLOBAL MARKET SHARE FOR "SILENT" CANCERS, 2013 AND 2019 (%)	39
FIGURE 3 GLOBAL MARKET FOR INCRETIN-BASED THERAPEUTICS, 2012-2019 (\$ MILLIONS)	54
FIGURE 4 THE INCRETIN EFFECT ILLUSTRATED	57
FIGURE 5 PERCENTAGE OF DISPENSED PRESCRIPTIONS FOR NON-INSULIN ANTIDIABETICS, 2012 (%)	58
FIGURE 6 PERCENTAGE OF DISPENSED PRESCRIPTIONS FOR GLP-1 RECEPTOR AGONISTS, 2012 (%)	60
FIGURE 7 PERCENTAGE OF DISPENSED PRESCRIPTIONS FOR DPP-4 INHIBITORS, 2012 (%)	60
FIGURE 8 ADA'S STANDARD OF MEDICAL CARE IN DIABETES, 2014	74
FIGURE 9 NUMBER OF COMMERCIALIZED INCRETIN-BASED THERAPEUTICS, 2014 AND 2019 (UNITS)	93
FIGURE 10 MARKET SHARE OF INCRETIN-BASED THERAPEUTICS, BY THERAPEUTIC AREA, 2014 AND 2019 (% OF REVENUE BY THERAPEUTIC AREA)	94
FIGURE 11 MARKET SHARE OF COMMERCIALIZED INCRETIN-BASED THERAPEUTICS, BY INCRETIN TYPE, 2014 AND 2019 (% OF REVENUE BY INCRETIN TYPE)	96
FIGURE 12 MARKET SHARE OF COMMERCIALIZED GLP-1 RECEPTOR AGONISTS, BY DOSING FREQUENCY, 2014 AND 2019 (%)	96
FIGURE 13 GLOBAL REVENUES OF ORPHAN DRUGS BY TYPE, 2012-2019 (\$ MILLIONS)	107
FIGURE 14 GLOBAL MARKET SHARE FOR INFECTIOUS DISEASE DIAGNOSTIC, VACCINE AND PHARMACEUTICAL PRODUCTS, 2016 AND 2021 (%)	128
FIGURE 15 GLOBAL IMMUNIZATION COVERAGE, 2014 (%)	134